ArticleCancer research communications2022
Comprehensive assessment of anaplastic lymphoma kinase in localized and metastatic prostate cancer reveals targetable alterations.
Open access · goldAbstract read
In one paragraph
Article in Cancer research communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 14 citations in OpenAlex.
- Clonal relationship in a rare pulmonary mixed tumor: shared ALK fusion in atypical carcinoid and adenocarcinoma-a case report.Translational lung cancer research · 2026Article
- Small Cell Transformation of Metachronous ALK + ve Lung and Prostatic Adenocarcinoma following Initial Response to Ceritinib and Androgen Deprivation Therapies and Metastases to Two Different Organs: Guidance through FDG-PET/CT andWorld journal of nuclear medicine · 2026Article
- Endocrine cancer organoids in basic and translational medical research.Science China. Life sciences · 2025Review
- Patterns of intra- and intertumor phenotypic heterogeneity in lethal prostate cancer.The Journal of clinical investigation · 2025Article
- Gilteritinib suppresses prostate cancer cell proliferation and migration and induces ER stress-mediated non-autophagic cytoplasmic vacuolization cell death.Medical oncology (Northwood, London, England) · 2025Article
- Exploring potential therapeutic combinations for castration-sensitive prostate cancer using supercomputers: a proof of concept study.Scientific reports · 2024Article
- Article
- Single-cell analysis of treatment-resistant prostate cancer: Implications of cell state changes for cell surface antigen-targeted therapies.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlates.NPJ precision oncology · 2024Article
- Single Cell Analysis of Treatment-Resistant Prostate Cancer: Implications of Cell State Changes for Cell Surface Antigen Targeted Therapies.bioRxiv : the preprint server for biology · 2024Article
- Organoids: An Emerging Precision Medicine Model for Prostate Cancer Research.International journal of molecular sciences · 2024Review
- Characterization of HOXB13 expression patterns in localized and metastatic castration-resistant prostate cancer.The Journal of pathology · 2024Article
- ASSESSMENT OF CELL SURFACE TARGETS IN METASTATIC PROSTATE CANCER: EXPRESSION LANDSCAPE AND MOLECULAR CORRELATES.Research square · 2023Article
- ALK fusions in the pan-cancer setting: another tumor-agnostic target?NPJ precision oncology · 2023Review
- Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer.JCI insight · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 3 institutions in 2 countries.
Radhika A PatelDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Ilsa ColemanDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Martine P RoudierDepartment of Urology, University of Washington, Seattle, WA, USA.
Eric Q KonnickDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
Brian HanrattyDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Ruth DumpitDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Jared M LucasDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Lisa S AngDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Jin-Yih LowDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Maria S TretiakovaDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
Gavin HaDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
John K LeeDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Lawrence D TrueDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
Angelo M De MarzoSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, MD, Baltimore, USA.
Peter S NelsonDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Colm MorrisseyDepartment of Urology, University of Washington, Seattle, WA, USA.
Colin C PritchardDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
Michael C HaffnerDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa · ZAUniversity of Washington · USJohns Hopkins University · US
Funding
Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4MTRANSCRIPTOME AND PROTEOME STRATIFICATION OF PROSTATE ADENOCARCINOMA PHENOTYPESP50CA097186 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PETER S NELSON · 2002 to 2026
$58.1MTRANSGENIC MODELS FOR PROSTATE CANCER AND AUTOIMMUNITYP50CA058236 · NCI · JOHNS HOPKINS UNIVERSITY · PI DENMEADE, SAMUEL R · 1992 to 2020
$43.9MSteroid Metabolism in Castration-Resistant Prostate CancerP01CA163227 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI PETER S NELSON · 2013 to 2026
$25.0MThe MSKCC-UW/Fred Hutch Prostate Cancer Drug Resistance and Sensitivity CenterU54CA224079 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CARVER, BRETT STEWART · 2017 to 2021
$6.8MDefining and Targeting Lineage Transition Programs Operative in AR Pathway Independent Prostate CancerR01CA234715 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI NELSON, PETER S · 2020 to 2024
$2.0MHigh-Performance Compute Cluster for Comprehensive Cancer and Infectious Diseases ResearchS10OD028685 · OD · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BRADLEY, PHILIP · 2020 to 2020
$2.0MNCI NIH HHS P01 CA163227NCI NIH HHS P30 CA015704NCI NIH HHS P50 CA058236NCI NIH HHS P50 CA097186NCI NIH HHS R01 CA234715NCI NIH HHS U54 CA224079NIH HHS S10 OD028685
Abstract
Anaplastic lymphoma kinase (ALK) is a tyrosine kinase with genomic and expression changes in many solid tumors. ALK inhibition is first line therapy for lung cancers with
Indexed as
Lung NeoplasmsProstatic NeoplasmsAnaplastic Lymphoma KinaseHumansMaleProtein Kinase InhibitorsProtein-Tyrosine KinasesAnaplastic Lymphoma KinaseProtein Kinase InhibitorsProtein-Tyrosine Kinases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.